MRTNZ

MRTNZ Investment Office · S&P 500 · The 360 Vantage

LLY · NYSE

Eli Lilly and Company

Health Care · Biotechnology: Pharmaceutical Preparations

Reference price$1,220.66As of Jul 28, 2026
Market capitalization$1,150B
52-week range$623.78–$1,249.45
S&P 500 portfolio weight1.48%
Data qualitycomplete

Street view

Analyst targets

Published sell-side aggregation—not an MRTNZ forecast.

Low$1,135.00-7.0% vs. reference
Average$1,350.89+10.7% vs. reference
High$1,600.00+31.1% vs. reference
19 Buy2 Hold0 Sell

Forward calendar

Current earnings expectations

Consensus may change until the company reports.

Expected reportAug 5, 2026Jun 2026
Consensus EPS$6.714 estimates
Expected range$5.83–$8.80Low to high EPS
Dec 2026$35.03Street EPS consensus
Dec 2027$44.98Street EPS consensus
Dec 2028$54.27Street EPS consensus

Reported results

Annual financial snapshot

Fiscal period ended Dec 31, 2025.

MetricCurrentPrior
Revenue+44.7% YoY$65.18B$45.04B
Operating income$26.3B$12.9B
Net income$20.64B$10.59B
Operating cash flow$16.81B$8.82B
Capital expenditures($7.84B)($5.06B)

Current context

Related news

Company-linked articles surfaced by Nasdaq.

The Motley Fool

4 Stocks That Can 4x Your Money in 4 Years

BNK Invest

Notable Tuesday Option Activity: SNDK, LLY, CORZ

Zacks

INCY Q2 Earnings & Revenues Beat on Higher Sales, '26 View Raised

Evidence

Sources & method

Nasdaq quote →Nasdaq summary →Earnings forecast →Annual financials →Official S&P 500-tracking holdings →

Facts, estimates, and scenarios are kept separate. Analyst targets and EPS expectations are third-party estimates, not MRTNZ forecasts. Index weight uses the official IVV portfolio as the denominator. Illustrative research, not investment advice.